Recent Developments at Pharma Companies: Special Research on Discovery Labs, Enzon, Fate Therapeutics, Genetic Technologies, and Genocea Biosciences
NEW YORK, February 16, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Discovery Labs (NASDAQ: DSCO), Enzon (NASDAQ: ENZN), Fate Therapeutics (NASDAQ: FATE), Genetic Technologies (NASDAQ: GENE), and Genocea Biosciences (NASDAQ: GNCA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
DSCO Research Report: ( http://get.analystsreview.com/pdf/?c=Discovery%20Labs&d=16-Feb-2015&s=DSCO ),
ENZN Research Report: ( http://get.analystsreview.com/pdf/?c=Enzon&d=16-Feb-2015&s=ENZN ),
FATE Research Report: ( http://get.analystsreview.com/pdf/?c=Fate%20Therapeutics&d=16-Feb-2015&s=FATE ),
GENE Research Report: ( http://get.analystsreview.com/pdf/?c=Genetic%20Technologies&d=16-Feb-2015&s=GENE ),
GNCA Research Report: ( http://get.analystsreview.com/pdf/?c=Genocea%20Biosciences&d=16-Feb-2015&s=GNCA ).
============
--
Analyst Update: Partnerships, Quarterly Results, 2015 Objectives, and Corporate Updates
Reviewed by: Rohit Tuli, CFA®
The U.S. stocks closed higher on Friday with S&P 500 hitting an intraday record and the Dow Jones Industrial Average reaching its highest point so far this year. The Dow industrials added 46.97 points, or 0.26%, to 18019.35. The S&P 500 rose 8.51 points, or 0.41%, to 2096.99, and the Nasdaq Composite gained 36.22 points, or 0.75%, to 4893.84. The markets got a boost on hopes of a deal between Greece and its creditors. The continued redound in oil prices as well as strong economic data out of Europe also helped the markets in the rally. European markets also rose, driven by the Friday release of German data that showed the country's economy had grown in 2014's fourth quarter at a better-than-expected rate. Asia stocks mostly closed higher on Friday, following a global advance overnight, supported by reports of a new cease-fire agreement between Russia and Ukraine, Sweden's surprise move to cut its main rate into negative territory, and Greece agreeing to talks over its debt problems.
Discovery Laboratories, Inc. (Discovery Labs) has partnered with March of Dimes for their 2015 Prematurity Awareness Campaign. Through this partnership, March of Dimes and Discovery Labs will share educational pieces for women of child bearing age in the five-county Philadelphia area to help educate mothers-to-be on prematurity and to foster awareness to help families in having full-term, healthy babies.
Enzon Pharmaceuticals, Inc. (Enzon) reported its Q3 2014 financial results with net income of $7.6 million or $0.17 per diluted share compared with $5.6 million or $0.13 per diluted share in Q3 2013. Enzon's operating income for the quarter also increased to $7.6 million from $5.1 million in Q3 2013.
Fate Therapeutics, Inc. (Fate Therapeutics) has announced its key 2015 objectives for the advancement of programmed cellular therapeutics pipeline. As a part of these objectives, the Company aims to report full data on the primary efficacy endpoint in mid-2015 from the phase 2 PUMA Study of PROHEMA.
Genetic Technologies Ltd (Genetic Technologies) announced that up to 6 new breast diagnosis/treatment centres are expected to begin offering its BREVAGenplus® to their at-risk patients in a systematic broad fashion in January to March with additional new breast and imaging centre customers expected to follow later in 2015.
Genocea Biosciences, Inc. (Genocea Biosciences) reported recent corporate highlights and financial results for the fourth quarter and full year 2014. Net loss for the quarter increased to $11.7 million for the fourth quarter, compared to a net loss of $6.3 million for the same period in 2013.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article